Double blind trial of bezafibrate in familial hypercholesterolaemia.

K A Wheeler, R J West, J K Lloyd, J Barley

A six month, double blind, crossover controlled trial of bezafibrate was conducted in 14 children with familial hypercholesterolaemia all of whom had a strong family history of early coronary heart disease. The bezafibrate was given twice daily in a dose of 10 to 20 mg/kg/day. The mean plasma total cholesterol concentration on bezafibrate was 22% lower than during the period on placebo and there was a moderate rise in high density lipoprotein cholesterol. Bezafibrate may be a useful adjunct to treatment in these children.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Manlhiot, C., Larsson, P., Gurofsky, R. C., Smith, R. W., Fillingham, C., Clarizia, N. A., Chahal, N., Clarke, J. T., McCrindle, B. W. (2009). Spectrum and Management of Hypertriglyceridemia Among Children in Clinical Practice. Pediatrics 123: 458-465 [Abstract] [Full Text]  
• Pasquali, S. K., Li, J. S. (2008). Prevention of Future Cardiovascular Disease in High-Risk Pediatric Patients: A Role for Lipid Lowering Therapy?. Circ Cardiovasc Qual Outcomes 1: 131-133 [Full Text]  
• Ardoin, S., Sandborg, C., Schanberg, L. (2007). Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 16: 618-626 [Abstract]  
• Haney, E. M., Huffman, L. H., Bougatsos, C., Freeman, M., Steiner, R. D., Nelson, H. D. (2007). Screening and Treatment for Lipid Disorders in Children and Adolescents: Systematic Evidence Review for the US Preventive Services Task Force. Pediatrics 120: e189-e214 [Abstract] [Full Text]  
• McCrindle, B. W., for the Writing Group, (2007). Summary of the American Heart Association's Scientific Statement on Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents. Arterioscler. Thromb. Vasc. Bio. 27: 982-985 [Full Text]  
• McCrindle, B. W., Urbina, E. M., Dennison, B. A., Jacobson, M. S., Steinberger, J., Rocchini, A. P., Hayman, L. L., Daniels, S. R. (2007). Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing. Circulation 115: 1948-1967 [Abstract] [Full Text]  
• Stein, E. A., Illingworth, D. R., Kwiterovich, P. O. Jr, Liacouras, C. A., Siimes, M. A., Jacobson, M. S., Brewster, T. G., Hopkins, P., Davidson, M., Graham, K., Arensman, F., Knopp, R. H., DuJovne, C., Williams, C. L., Isaacsohn, J. L., Jacobsen, C. A., Laskarzewski, P. M., Ames, S., Gormley, G. J. (1999). Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia: A Randomized Controlled Trial. JAMA 281: 137-144 [Abstract] [Full Text]